Genmab A/S FY2026 EPS Estimate Reduced by Leerink Partnrs

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities research analysts at Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for shares of Genmab A/S in a report issued on Sunday, October 12th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per share of $1.12 for the year, down from their prior forecast of $1.99. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

A number of other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Genmab A/S in a report on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a report on Tuesday, September 23rd. Wall Street Zen upgraded shares of Genmab A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 26th. Finally, Truist Financial raised their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Stock Down 0.1%

Shares of GMAB opened at $32.72 on Wednesday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $33.63. The company has a market capitalization of $21.01 billion, a P/E ratio of 16.44, a price-to-earnings-growth ratio of 1.85 and a beta of 0.98. The firm has a 50 day moving average of $27.51 and a 200 day moving average of $23.13.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC boosted its stake in Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after purchasing an additional 1,464 shares during the period. Osaic Holdings Inc. lifted its holdings in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares in the last quarter. CWM LLC boosted its position in shares of Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after acquiring an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after acquiring an additional 1,070 shares during the last quarter. Finally, AlphaCore Capital LLC bought a new stake in Genmab A/S in the 2nd quarter valued at $44,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.